You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm will consolidate its businesses in newly-built headquarters in Fort Myers, Florida, which it plans to occupy around September.
Multinational nephrology firm Fresenius Medical Care eventually wants as many as 200,000 samples in its registry and aims to sequence 20,000 patients this year.
By extending Terra to the Microsoft Azure cloud, the Broad and Verily Life Sciences hope to facilitate better data sharing, analysis, and reuse.
The decision comes amid a general slowdown in the market, yet also showcases the continued appeal of ancestry-related applications.
Backed by large public companies and growing prospective data, the first molecular blood tests to screen for multiple cancers are approaching commercialization.
Some tests that detect multiple SARS-CoV-2 genes are serendipitously signaling new viral variants while still effectively detecting infections.
Some core labs are expecting long waitlists in 2021 as PacBio's HiFi reads draw interest from researchers looking to put together whole genomes.
Over the next year or so, the investigators plan to sequence the genomes of 3,000 patients with cancer, heart disease, diabetes, or neurological disorders.
The pace of development for CRISPR-based infectious disease assays increased as the pandemic progressed, more funding became available, and collaboration accelerated.
The two new tests, which have the capability to quantify a patient's viral load, have been designed without external RNA extraction or amplification steps.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.
In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.